ASHLEY DILLON: Open Payments
NPI 1427628361 · GRAND ISLAND, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,135 in 83 payments from 10 companies in 2025. Trend: 2023 $1,836 · 2024 $1,041 · 2025 $1,135
Food & beverage: $1,135
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 17 | $224 |
| Otsuka America Pharmaceutical, Inc. | 11 | $172 |
| Alkermes, Inc. | 13 | $163 |
| ABBVIE INC. | 18 | $135 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $118 |
| Neurocrine BioSciences, Inc. | 6 | $117 |
| Janssen Pharmaceuticals, Inc | 5 | $98 |
| Axsome Therapeutics, Inc. | 4 | $65 |
| Lundbeck LLC | 2 | $27 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: ARISTADA, UZEDY, REXULTI, VRAYLAR, CAPLYTA, INGREZZA, INVEGA SUSTENNA, AUSTEDO XR.
Industry payments across NE — which companies pay providers there.
